JP6035338B2 - 植物ステロイドおよびその使用 - Google Patents

植物ステロイドおよびその使用 Download PDF

Info

Publication number
JP6035338B2
JP6035338B2 JP2014530888A JP2014530888A JP6035338B2 JP 6035338 B2 JP6035338 B2 JP 6035338B2 JP 2014530888 A JP2014530888 A JP 2014530888A JP 2014530888 A JP2014530888 A JP 2014530888A JP 6035338 B2 JP6035338 B2 JP 6035338B2
Authority
JP
Japan
Prior art keywords
drug
drug conjugate
stigmasterol
disease
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014530888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526515A5 (enExample
JP2014526515A (ja
Inventor
マイケル デイビッドソン，
マイケル デイビッドソン，
ジョン エフ． アルネット，
ジョン エフ． アルネット，
サディック エルシャニ，
サディック エルシャニ，
ロエロフ ロンジェン，
ロエロフ ロンジェン，
Original Assignee
デイビッドソン ロペス， エルエルシー
デイビッドソン ロペス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイビッドソン ロペス， エルエルシー, デイビッドソン ロペス， エルエルシー filed Critical デイビッドソン ロペス， エルエルシー
Publication of JP2014526515A publication Critical patent/JP2014526515A/ja
Publication of JP2014526515A5 publication Critical patent/JP2014526515A5/ja
Application granted granted Critical
Publication of JP6035338B2 publication Critical patent/JP6035338B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014530888A 2011-09-16 2012-09-14 植物ステロイドおよびその使用 Expired - Fee Related JP6035338B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US61/535,661 2011-09-16
US201261675966P 2012-07-26 2012-07-26
US61/675,966 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016212948A Division JP2017019871A (ja) 2011-09-16 2016-10-31 植物ステロイドおよびその使用

Publications (3)

Publication Number Publication Date
JP2014526515A JP2014526515A (ja) 2014-10-06
JP2014526515A5 JP2014526515A5 (enExample) 2015-10-08
JP6035338B2 true JP6035338B2 (ja) 2016-11-30

Family

ID=47883793

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014530888A Expired - Fee Related JP6035338B2 (ja) 2011-09-16 2012-09-14 植物ステロイドおよびその使用
JP2016212948A Pending JP2017019871A (ja) 2011-09-16 2016-10-31 植物ステロイドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016212948A Pending JP2017019871A (ja) 2011-09-16 2016-10-31 植物ステロイドおよびその使用

Country Status (16)

Country Link
US (2) US10086082B2 (enExample)
EP (1) EP2755660B1 (enExample)
JP (2) JP6035338B2 (enExample)
KR (1) KR20140093661A (enExample)
CN (2) CN109384825A (enExample)
AU (1) AU2012308332A1 (enExample)
BR (1) BR112014006222A2 (enExample)
CA (1) CA2848979C (enExample)
EA (1) EA201490637A1 (enExample)
HK (1) HK1200358A1 (enExample)
IL (1) IL231541A0 (enExample)
IN (1) IN2014CN02688A (enExample)
MX (1) MX2014003260A (enExample)
PH (1) PH12014500596A1 (enExample)
SG (1) SG11201400652UA (enExample)
WO (1) WO2013040441A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964269A1 (en) 2013-03-08 2016-01-13 Allergan, Inc. Cyclosporine a-steroid conjugates
KR20150126032A (ko) 2013-03-08 2015-11-10 알러간, 인코포레이티드 스테로이드 약물과 직접 결합된 항생제 컨쥬게이트
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
WO2018132676A1 (en) * 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (ko) * 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
CN110051674A (zh) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 豆甾醇在制备治疗胃癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
WO2002089820A1 (en) * 2001-05-09 2002-11-14 Mediplex Corporation Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
JP2008533157A (ja) * 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
US8252755B2 (en) * 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CA2669355C (en) * 2006-11-06 2012-10-30 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
AU2011223730A1 (en) * 2010-03-02 2012-10-18 Imagenetix, Inc. Compositions comprising myristic acid and uses thereof

Also Published As

Publication number Publication date
EP2755660A4 (en) 2015-03-18
HK1200358A1 (en) 2015-08-07
US20150141390A1 (en) 2015-05-21
EA201490637A1 (ru) 2014-11-28
AU2012308332A1 (en) 2014-04-10
EP2755660A1 (en) 2014-07-23
CN109384825A (zh) 2019-02-26
BR112014006222A2 (pt) 2017-04-11
IN2014CN02688A (enExample) 2015-07-03
MX2014003260A (es) 2014-09-08
CN103987390A (zh) 2014-08-13
IL231541A0 (en) 2014-04-30
US20190083632A1 (en) 2019-03-21
CA2848979A1 (en) 2013-03-21
EP2755660B1 (en) 2019-11-06
JP2014526515A (ja) 2014-10-06
US10086082B2 (en) 2018-10-02
JP2017019871A (ja) 2017-01-26
CA2848979C (en) 2019-11-05
SG11201400652UA (en) 2014-09-26
KR20140093661A (ko) 2014-07-28
PH12014500596A1 (en) 2014-04-21
WO2013040441A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
JP6035338B2 (ja) 植物ステロイドおよびその使用
Jung et al. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor
Barnes Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease
CA2649940C (en) Drugs and uses to modulate inflammation, metabolic disorders and other conditions
Bruno et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
US8217025B2 (en) Drug screening and treatment methods
De Marino et al. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity
Lu et al. Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element
Huang et al. Th2A cells: The pathogenic players in allergic diseases
Ruiz et al. Azo-reductase activated budesodine prodrugs for colon targeting
Guo et al. MicroRNA-195a-5p inhibits mouse medullary thymic epithelial cells proliferation by directly targeting Smad7
El Kihel et al. New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines
Bratoeff et al. Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3
JP2023526315A (ja) 未成熟終止コドンの阻害剤としてのキナゾリン化合物
Saxena et al. Cholesterol: A prelate in cell nucleus and its serendipity
Turgut et al. Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis
Pfeifer et al. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol
Griffin et al. Biosynthesis of the neurosteroid 3α-hydroxy-4-pregnen-20-one (3αHP), a specific inhibitor of FSH release
JP2019167302A (ja) Ａｋｒ１ｃ３選択的阻害剤及びその用途
Viktorsson et al. Regulation of liver X receptor target genes by 22-functionalized oxysterols. Synthesis, in silico and in vitro evaluations
Hamon et al. Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma
de Mello Martins et al. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β, 6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by abiraterone
Tompkins et al. Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR 1 and PXR 2
Tang et al. Synthesis and cytotoxicity of novel steroidal C-20 oxime ester derivatives from 16-DPA
AL-Rida et al. SYNTHESIS, CHARACTERIZATION AND STUDY BIOLOGICAL ACTIVITY SOME NEW DERIVATIVES AMIDE AND PYRAZOLE–PYRAZOLINE OF STEROID ANALOGS.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161031

R150 Certificate of patent or registration of utility model

Ref document number: 6035338

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees